Chapter

Evidence-based treatment of lupus nephritis

Wai Y. Tse and Dwomoa Adu

in Rheumatology and the Kidney

Second edition

Published on behalf of Oxford University Press

Published in print April 2012 | ISBN: 9780199579655
Published online February 2013 | e-ISBN: 9780191763472 | DOI: http://dx.doi.org/10.1093/med/9780199579655.003.0032

Series: Oxford Clinical Nephrology Series

Evidence-based treatment of lupus nephritis

Show Summary Details

Preview

1. A summary of the recommendations of the management of SLE is shown in Table 5.1. 2. Complications of drug treatment account for much of the morbidity that develops in SLE, in particular complications of high-dose or chronic corticosteroids (infection, osteonecrosis, osteoporosis, coronary artery disease) and cyclophosphamide (infection, sterility, bladder toxicity and malignancy). 3. It is encouraging that mycophenolate mofetil has a less toxic side effect profile than cyclo-phosphamide. 4. The risk of infections is substantial in patients taking corticosteroids and immuno-suppressants. 5. Regular clinical review of the patient's condition, together with laboratory tests and urinalysis to detect marrow depression, disease activity or progressive disease is mandatory in the management of these patients.

Chapter.  5237 words. 

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.